A case of serotonin syndrome and mutism associated with methadone

Journal of Palliative Medicine

Volumn 9, Issue 6, 2006, Pages 1257-1259

  Bush, Eric ^a,b   Miller, Carol ^a   Friedman, Irwin ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Center for Hospice and Palliative Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEXTROPROPOXYPHENE; FENTANYL; FLUOXETINE; FLUVOXAMINE; HYDROCODONE; HYDROMORPHONE; METHADONE; N METHYL DEXTRO ASPARTIC ACID; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFANILAMIDE;

AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CASE REPORT; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; FEVER; HOSPITAL PATIENT; HUMAN; INCIDENCE; MENTAL HEALTH; MUTISM; MYOCLONUS; NAUSEA; NEUROMUSCULAR DISEASE; PAIN; PALLIATIVE THERAPY; POLYPHARMACY; SEROTONIN SYNDROME; SIDE EFFECT; SYMPTOMATOLOGY; VOMITING;

AGED; FEMALE; HUMANS; METHADONE; MUTISM; NARCOTICS; PALLIATIVE CARE; SEROTONIN SYNDROME; UNITED STATES;

EID: 33846016606     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2006.9.1257     Document Type: Article

References (16)

1. Sampson E, Warner JP: Serotonin syndrome: potentially fatal but difficult to recognize. Br J Gen Pract 1999;49:867-868.
2. Martin T: Serotonin syndrome. Ann Emerg Med 1996;28:520-526.
3. Graudins A, Stearman A, Chan B: Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16:615-619.
4. Isbister GK, Bowe SJ, Dawson A, Whyte IM: Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004;42:277-285.
5. Watson WA, Litovitz TL, Rodgers GC Jr, Klein-Schwartz W, Youniss J, Rose SR, Borys D, May ME: 2002 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003;21:353-421.
6. Sternbach H: The serotonin syndrome. Am J Psychiatry 1991;148:705-713.
7. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med 2003;96:635-642.
8. Mason PJ, Morris VA, Balcezak TJ: Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000;79:201-209.
9. Bodner RA, Lynch T, Lewis L, Kahn D: Serotonin syndrome. Neurology 1995;45:219-223.
10. Hernandez JL, Ramos FJ, Infante J, Rebollo M, Gonzalez-Macias J: Severe serotonin syndrome induced by mirtazapine monotherapy. Ann Pharmacother 2002;36:641-643.
11. Brown TM, Skop BP, Mareth TR: Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996;30:527-533.
12. Yamada J, Sugimoto Y, Horisaka K: The behavioral effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur J Pharmacol 1988;154:299-304.
13. Saper CB: Brain stem modulation of sensation, movement, and consciousness. In: Kandel ER, Schwartz JH, Jessell TM (eds): Principles of Neural Science, 4th ed. New York: McGraw-Hill, 2000, pp. 896.
14. Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005;17;352:1112-1120.
15. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-469.
16. Ubogu EE, Katirji B: Mirtazapine-induced serotonin syndrome. Clin Neuropharmacol 2003;26:54-57.